Domperidone for Dyspepsia

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Dyspepsia+10 More
Domperidone - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at how well domperidone works to treat gastrointestinal disorders. Domperidone may help control symptoms like pain, bloating, and nausea and vomiting, by stimulating the stomach to empty itself of food.

Eligible Conditions
  • Dyspepsia
  • Gastroparesis
  • Digestive System Disorders
  • Esophagitis
  • Heartburn
  • Gastroesophageal reflux disease
  • Nausea

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to 30 days after completion of study treatment

Day 30
Change in patients' self-report of symptoms
Baseline to 8 weeks
Attenuation of symptoms associated with disorder(s) of gastrointestinal motility, measured by change in Gastroparesis Cardinal Symptom Index (GSCI) score from baseline
Day 30
Incidence of toxicities assessed according to the Common Terminology Criteria for Adverse Events version 4.0

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Treatment (domperidone)
1 of 1

Experimental Treatment

200 Total Participants · 1 Treatment Group

Primary Treatment: Domperidone · No Placebo Group · Phase 3

Treatment (domperidone)Experimental Group · 2 Interventions: Questionnaire Administration, Domperidone · Intervention Types: Other, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Domperidone
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 30 days after completion of study treatment

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,005 Previous Clinical Trials
41,301,727 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,783 Previous Clinical Trials
1,784,658 Total Patients Enrolled
Mehnaz ShafiPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
284 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.